CRTX
Price:
$1.95
Market Cap:
$234.42M
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Industry
Biotechnology
IPO Date
2019-05-09
Stock Exchange
NASDAQ
Ticker
CRTX
According to Cortexyme, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.66. This represents a change of -50.52% compared to the average of -1.33 of the last 4 quarters.
The mean historical PE Ratio of Cortexyme, Inc. over the last ten years is -20.18. The current -0.66 PE Ratio has changed 226.12% with respect to the historical average. Over the past ten years (40 quarters), CRTX's PE Ratio was at its highest in in the June 2024 quarter at -0.28. The PE Ratio was at its lowest in in the September 2018 quarter at -70.29.
Average
-20.18
Median
-7.36
Minimum
-57.93
Maximum
-0.41
Discovering the peaks and valleys of Cortexyme, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 201.43%
Maximum Annual PE Ratio = -0.41
Minimum Annual Increase = -90.09%
Minimum Annual PE Ratio = -57.93
| Year | PE Ratio | Change |
|---|---|---|
| 2024 | -1.42 | 14.27% |
| 2023 | -1.25 | 201.43% |
| 2022 | -0.41 | -90.09% |
| 2021 | -4.17 | -60.46% |
| 2020 | -10.55 | -63.50% |
| 2019 | -28.89 | -49.15% |
| 2018 | -56.81 | -1.93% |
The current PE Ratio of Cortexyme, Inc. (CRTX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-1.03
5-year avg
-3.56
10-year avg
-20.18
Cortexyme, Inc.’s PE Ratio is greater than Surface Oncology, Inc. (-0.91), greater than Achilles Therapeutics plc (-1.66), greater than Landos Biopharma, Inc. (-6.56), greater than Jade Biosciences, Inc. (-9.09), less than Reneo Pharmaceuticals, Inc. (73.07), greater than IGM Biosciences, Inc. (-1.46), less than TCR2 Therapeutics Inc. (-0.38), greater than Kronos Bio, Inc. (-0.83), less than Heat Biologics, Inc. (-0.00), greater than Berkeley Lights, Inc. (-0.84),
| Company | PE Ratio | Market cap |
|---|---|---|
| -0.91 | $65.08M | |
| -1.66 | $60.83M | |
| -6.56 | $71.68M | |
| -9.09 | $488.73M | |
| 73.07 | $60.84M | |
| -1.46 | $77.50M | |
| -0.38 | $58.11M | |
| -0.83 | $53.65M | |
| -0.00 | $61.07M | |
| -0.84 | $86.61M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cortexyme, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Cortexyme, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Cortexyme, Inc.'s PE Ratio?
How is the PE Ratio calculated for Cortexyme, Inc. (CRTX)?
What is the highest PE Ratio for Cortexyme, Inc. (CRTX)?
What is the 3-year average PE Ratio for Cortexyme, Inc. (CRTX)?
What is the 5-year average PE Ratio for Cortexyme, Inc. (CRTX)?
How does the current PE Ratio for Cortexyme, Inc. (CRTX) compare to its historical average?